At Cargill, were helping customers navigate these challenges through application-driven solutions
There is no evidence that shows she used GLP-1s to lose weight
According to the drug's prescribing information, these potential risks are: An allergic reaction (hypersensitivity) Severe low blood sugar in people with type 2 diabetes, especially those taking insulin or sulfonylureas Complications related to diabetic retinopathy in those with type 2 diabetes Acute pancreatitis or gallbladder disease Acute kidney injury Increases in heart rate Suicidal ideation or behavior Lastly, Wegovy may increase the risk of certain thyroid tumors but this has only been observed in rodent studies
Wegovy: weight-loss licence), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide
The usual starting dose is 3 mg once daily, potentially increasing to 7 mg and then to a maximum of 14 mg, based on individual responses and tolerability
Remember that weight management is a long-term commitment requiring sustainable approaches
